Including results for dynavax investor relations
Search only for dvax investor relations
Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and ...
People also ask
Is Dvax a buy sell or hold?
Who are DVAX competitors?
What is the guidance of Dynavax?
What is the market share of Heplisav-B?
Dynavax Technologies is focused on leveraging the power of the body's innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.
Feb 22, 2024 · Total revenues for the fourth quarter of 2023 were $55.6 million, compared to $184.5 million for the fourth quarter of 2022, and $232.3 million ...
8 days ago · EMERYVILLE, Calif., April 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ... investors.dynavax.com/events-presentations.
Nov 3, 2023 · I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin ...
Nov 2, 2023 · HEPLISAV-B vaccine net product revenue was $62.3 million for the third quarter of 2023, compared to $37.5 million for the third quarter of 2022, ...
Feb 23, 2024 · I would now like to turn the call over to Paul Cox, Vice President, Investor Relations and Corporate Communications. You may begin ...